Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...
“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...
With studies showing potential for SGLT2 inhibitors in heart failure ... Others were concerned that there was uncertainty about the mechanism. Cost was also a concern raised by cautious ...
In addition: “SGLT2 inhibitors, unlike thiazolidinediones [a commonly used class of diabetes drugs], have a tendency to increase fluid excretion by a mechanism that depends on osmotic diuresis.
SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...
SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...
Teams of researchers are investigating empagliflozin and dapagliflozin in patients with autosomal dominant polycystic kidney disease (AD PKD).
But, "the mechanism of action is open to speculation," she said. SGLT2 inhibitors have diuretic and anti-inflammatory effects ...
GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...
The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.
GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...
Phlorizin opened the way for a new promising class of antidiabetic agents. The main action of SGLT2 inhibitors is the induction of glucosuria and osmotic diuresis. Further features, benefits and ...